Score Overview
Explore the 2021 public Archive ranking →
Where Eyepoint Pharmaceuticals Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- EYPT
2016: 63.1% · 2021: 96.2% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 3.42 | — |
1 Year2025-09-29 | $ 14.05 | -75.66% |
5 Years2021-09-29 | $ 10.28 | -66.73% |
10 Years2016-09-29 | $ 31.80 | -89.25% |
20 Years2006-09-29 | $ 96.00 | -96.44% |
All Time2005-01-27 | $ 401.60 | -99.15% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2005-01-27 |
|---|---|---|---|---|---|---|
| Price | $ 3.42 | $ 14.05 | $ 10.28 | $ 31.80 | $ 96.00 | $ 401.60 |
| Return | — | -75.66% | -66.73% | -89.25% | -96.44% | -99.15% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 2M | -$ 306M | $ 180M |
| 2025 | $ 31M | -$ 231M | $ 306M |
| 2024 | $ 43M | -$ 130M | $ 370M |
| 2023 | $ 46M | -$ 70M | $ 331M |
| 2022 | $ 41M | -$ 102M | $ 144M |
| 2021 | $ 36M | -$ 58M | $ 211M |
| 2020 | $ 34M | -$ 45M | $ 44M |
| 2019 | $ 20M | -$ 56M | $ 22M |
| 2018 | $ 2M | -$ 53M | $ 38M |
| 2017 | $ 7M | -$ 18M | $ 16M |
| 2016 | $ 1M | -$ 21M | $ 28M |
| 2015 | $ 26M | $ 6M | $ 28M |
| 2014 | $ 3M | -$ 13M | $ 18M |
| 2013 | $ 2M | -$ 11M | $ 10M |
| 2012 | $ 3M | -$ 24M | $ 14M |
| 2011 | $ 4M | -$ 8M | $ 24M |
| 2010 | $ 23M | $ 8M | $ 17M |
| 2009 | $ 12M | -$ 2M | $ 6M |
| 2008 | $ 3M | -$ 75M | $ 9M |
| 2007 | $ 2M | -$ 103M | $ 2M |
| 2006 | $ 1M | -$ 20M | $ 4M |
| IPO2005 | $ 629.52K | -$ 11M | $ 9M |
Eyepoint Pharmaceuticals Inc fundamental performance
Between 2015 and 2025, revenue grew from $ 26M to $ 31M and net income went from $ 6M to -$ 231M. Revenue increased in 6 of those 10 years; net income in 3.
Across Eyepoint Pharmaceuticals Inc's full reported history, from 2005 to 2025, revenue grew from $ 629.52K to $ 31M and net income went from -$ 11M to -$ 231M. Revenue increased in 62% of the years measured; net income in 38%.
Eyepoint Pharmaceuticals Inc currently holds a 20-year HDB Score of 2.3 out of 10. How the HDB Score is calculated.
Membership
Continue EYPT’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
